27 completed, 3 terminated, 1 unknown. 31 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 31 | Completed 27, Terminated 3, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow vehicle gel: new trials by email Literature Review of vehicle gel trials Research Report on vehicle gel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib - Gorlin Syndrome | Phase 3 | Completed | Sol-Gel Technologies, Ltd. | 113 | 2024-03-17 | 2026-09-18 |
| A Phase 3 Molluscum Contagiosum Efficacy and Safety Study SB206 10.3% berdazimer, vehicle gel - Molluscum Contagiosum | Phase 3 | Completed | Novan, Inc. | 891 | 2020-09-01 | 2023-01-26 |
| A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery Granexin® gel 100 μM, Granexin® gel 200 μM, Vehicle gel - Mammoplasty, Scarring | Phase 2 / Phase 3 | Completed | Xequel Bio, Inc. | 184 | 2020-07-01 | 2022-06-06 |
| A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC SB206 12%, Placebo - Molluscum Contagiosum | Phase 3 | Completed | Novan, Inc. | 355 | 2019-06-13 | 2023-03-23 |
| A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1) SB206 12%, Placebo - Molluscum Contagiosum | Phase 3 | Completed | Novan, Inc. | 352 | 2019-06-03 | 2022-12-27 |
| Phase 3 Study to Evaluate the Safety and Efficacy of Galnobax® in Treating Diabetic Foot Ulcers Esmolol Hydrochloride, Only Standard of Care, Vehicle Gel - Diabetic Foot Ulcer | Phase 3 | Completed | Novalead Pharma Private Limited | 176 | 2018-12-26 | 2023-09-22 |
| A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer Granexin gel, Vehicle gel - Diabetic Foot Ulcers | Phase 3 | Terminated | Xequel Bio, Inc. | 124 | 2018-11-21 | 2020-05-29 |
| A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp ingenol disoxate gel 0.018%, ingenol disoxate gel 0.037%, Vehicle gel - Actinic Keratosis, Squamous Cell Carcinoma | Phase 3 | Terminated | LEO Pharma | 563 | 2017-06-16 | 2025-03-11 |
| Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa Oleogel-S10, Control gel - Epidermolysis Bullosa | Phase 3 | Completed | Amryt Research Limited | 223 | 2017-03-29 | 2023-07-20 |
| Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses GDC 695, Diclofenac Sodium Gel, 3%, Vehicle gel - Actinic Keratosis | Phase 3 | Completed | Balmoral Medical company | 665 | 2016-10-27 | 2020-01-07 |
| LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery Loteprednol Etabonate Ophthalmic Gel dosed TID, Loteprednol Etabonate Ophthalmic Gel dosed BID, Vehicle Gel - Cataract, Pain | Phase 3 | Completed | Bausch & Lomb Incorporated | 600 | 2016-06-01 | 2021-01-08 |
| P3 Study in Acne Comparing Once Daily SB204 and Vehicle SB204 4%, Vehicle Gel - Acne Vulgaris | Phase 3 | Completed | Novan, Inc. | 1307 | 2016-02-22 | 2023-07-24 |
| P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne SB204 4%, Vehicle Gel - Acne Vulgaris | Phase 3 | Completed | Novan, Inc. | 1330 | 2016-02-19 | 2023-07-24 |
| Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up LEO 43204 gel, Vehicle gel - Actinic Keratosis | Phase 3 | Completed | LEO Pharma | 383 | 2015-11-13 | 2025-03-10 |
| Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up LEO43204 gel, Vehicle gel - Actinic Keratosis | Phase 3 | Completed | LEO Pharma | 391 | 2015-11-01 | 2025-03-13 |
| Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up LEO 43204 gel, Vehicle gel - Actinic Keratosis | Phase 3 | Completed | LEO Pharma | 373 | 2015-11-01 | 2025-03-10 |
| Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up LEO 43204 gel, Vehicle gel - Actinic Keratosis | Phase 3 | Completed | LEO Pharma | 437 | 2015-11-01 | 2025-03-10 |
| Evaluate Therapeutic Equivalence and Safety of Two Clindamycin Phosphate and Benzoyl Peroxide Gels in Acne Vulgaris Clindamycin Phosphate / Benzoyl Peroxide Gel, Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%, Placebo (Vehicle Gel) - Acne Vulgaris | Phase 3 | Completed | Watson Laboratories, Inc. | 708 | 2012-07-01 | 2013-02-11 |
| Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp Ingenol mebutate gel, 0.015%, Vehicle gel - Actinic Keratosis | Phase 3 | Completed | LEO Pharma | 463 | 2012-05-01 | 2025-03-10 |
| Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne Epiduo/Tactuo, vehicle gel, doxycycline 200mg - Acne | Phase 3 | Completed | Galderma R&D | 266 | 2011-11-01 | 2021-02-18 |
Showing 20 of 31. Sign in to see all of them.
Keratosis, Actinic (12) · Acne Vulgaris (8) · Molluscum Contagiosum (3) · Diabetic Foot (2) · Pain (2) · Basal Cell Nevus Syndrome (1) · Carcinoma, Squamous Cell (1) · Cataract (1) · Cicatrix (1) · Diabetes Complications (1) · Diabetes Mellitus (1) · Diabetic Neuropathies (1) · Epidermolysis Bullosa (1) · Neuralgia (1) · Rosacea (1)
LEO Pharma (6) · Novan, Inc. (5) · Peplin (4) · Galderma R&D (2) · Stiefel, a GSK Company (2) · Xequel Bio, Inc. (2) · Amryt Research Limited (1) · Balmoral Medical company (1) · Bausch & Lomb Incorporated (1) · G&E Herbal Biotechnology Co., LTD (1) · GlaxoSmithKline (1) · Irmandade da Santa Casa de Misericordia de Sao Paulo (1) · Lisa E. Maier (1) · Novalead Pharma Private Limited (1) · Sol-Gel Technologies, Ltd. (1)
United States (23) · Canada (7) · Australia (5) · Germany (5) · France (4) · United Kingdom (4) · Spain (3) · Belize (2) · Brazil (2) · Hungary (2) · India (2) · Italy (2) · Argentina (1) · Austria (1) · Chile (1)
Joyce Rico, MD (2) · Adelaide Hebert, MD (1) · Amy Paller, MD (1) · Ashu Rastogi, MD (1) · C. William Hanke, MD (1) · Claus Garbe, MD (1) · Daniel M Siegel, MD (1) · Denise Ramjit (1) · Diane Thiboutot, MD (1) · Eugene Bauer, MD (1) · Hamm-Ming Sheu, MD (1) · Jerry Tan (1) · Johannes S Kern, MD PhD (1) · John L Capicchioni (1)
PMID 22417254, PMID 34909721, PMID 24934963, PMID 31186047, PMID 35587172, PMID 35830173, PMID 36287306, PMID 37184839, PMID 42205007
2016 (1), 2017 (1), 2023 (1)